These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 20647188)

  • 1. Don't mess with the DSMB.
    Drazen JM; Wood AJ
    N Engl J Med; 2010 Jul; 363(5):477-8. PubMed ID: 20647188
    [No Abstract]   [Full Text] [Related]  

  • 2. Ezetimibe and cancer--an uncertain association.
    Drazen JM; D'Agostino RB; Ware JH; Morrissey S; Curfman GD
    N Engl J Med; 2008 Sep; 359(13):1398-9. PubMed ID: 18765434
    [No Abstract]   [Full Text] [Related]  

  • 3. Identifying and addressing safety signals in clinical trials.
    Fleming TR
    N Engl J Med; 2008 Sep; 359(13):1400-2. PubMed ID: 18768938
    [No Abstract]   [Full Text] [Related]  

  • 4. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
    Rossebø AB; Pedersen TR; Boman K; Brudi P; Chambers JB; Egstrup K; Gerdts E; Gohlke-Bärwolf C; Holme I; Kesäniemi YA; Malbecq W; Nienaber CA; Ray S; Skjaerpe T; Wachtell K; Willenheimer R;
    N Engl J Med; 2008 Sep; 359(13):1343-56. PubMed ID: 18765433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More on DSMBs.
    Rosenblatt M; Kim PS
    N Engl J Med; 2011 May; 364(19):1879-80. PubMed ID: 21561365
    [No Abstract]   [Full Text] [Related]  

  • 6. Preliminary observations from preliminary trial results: have we finally had enough?
    Taylor AJ; Nissen SE
    Circ Cardiovasc Qual Outcomes; 2008 Sep; 1(1):54-7. PubMed ID: 20031788
    [No Abstract]   [Full Text] [Related]  

  • 7. At sea with SEAS: the first clinical endpoint trial for ezetimibe, treatment of patients with mild to moderate aortic stenosis, ends with mixed results and more controversy.
    Hamilton-Craig I; Kostner K; Colquhoun D; Woodhouse S
    Heart Lung Circ; 2009 Oct; 18(5):343-6. PubMed ID: 19586799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of cancer and mortality in patients from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial.
    Green A; Ramey DR; Emneus M; Iachina M; Stavem K; Bolin K; McNally R; Busch-Sørensen M; Willenheimer R; Egstrup K; Kesäniemi YA; Ray S; Basta N; Kent C; Pedersen TR
    Am J Cardiol; 2014 Nov; 114(10):1518-22. PubMed ID: 25267716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Premature release of data from clinical trials of ezetimibe.
    Califf RM; Harrington RA; Blazing MA
    N Engl J Med; 2009 Aug; 361(7):712-7. PubMed ID: 19675335
    [No Abstract]   [Full Text] [Related]  

  • 10. Hypercholesterolaemia: Clarifications from adverse drug reactions agency.
    Cox A
    BMJ; 2008 Sep; 337():a1669. PubMed ID: 18796483
    [No Abstract]   [Full Text] [Related]  

  • 11. In brief: Ezetimibe/simvastatin (Vytorin) in chronic kidney disease.
    Med Lett Drugs Ther; 2012 Jan; 54(1381):4. PubMed ID: 22233589
    [No Abstract]   [Full Text] [Related]  

  • 12. Reasons to be cautious about cholesterol lowering drugs.
    Struthers M
    BMJ; 2008 Sep; 337():a1493. PubMed ID: 18768557
    [No Abstract]   [Full Text] [Related]  

  • 13. Increased epistaxis with use of ezetimibe/simvastatin.
    Shah B; McAllister A; Davidson TM
    Ann Pharmacother; 2009 Sep; 43(9):1545. PubMed ID: 19671801
    [No Abstract]   [Full Text] [Related]  

  • 14. Rosiglitazone and the FDA.
    Joffe HV; Parks MH; Meyer RJ; Jenkins JK; Temple R
    N Engl J Med; 2007 Oct; 357(17):1775-6; author reply 1777. PubMed ID: 17761586
    [No Abstract]   [Full Text] [Related]  

  • 15. The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.
    Hiatt WR; Kaul S; Smith RJ
    N Engl J Med; 2013 Oct; 369(14):1285-7. PubMed ID: 23992603
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA committee urges tight restrictions on rosiglitazone.
    Roehr B
    BMJ; 2010 Jul; 341():c3862. PubMed ID: 20639290
    [No Abstract]   [Full Text] [Related]  

  • 17. Ezetimibe/simvastatin.
    Montecucco F; Quercioli A; Mach F
    Expert Opin Drug Saf; 2009 Nov; 8(6):715-25. PubMed ID: 19968571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amid lingering questions, FDA reprieves LDL cholesterol-lowering medication.
    Mitka M
    JAMA; 2009 Feb; 301(8):813-5. PubMed ID: 19244181
    [No Abstract]   [Full Text] [Related]  

  • 19. Analyses of cancer data from three ezetimibe trials.
    Nissen SE
    N Engl J Med; 2009 Jan; 360(1):86-7; author reply 87. PubMed ID: 19118312
    [No Abstract]   [Full Text] [Related]  

  • 20. The Avandia debate: an unhappy conclusion.
    Bloomgarden Z; Handelsman Y
    J Diabetes; 2010 Dec; 2(4):221-2. PubMed ID: 20923505
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.